How much was AbbVie's immunology revenue?

Immunology revenue reached $7.29 billion in Q1 2026.

Which drugs are driving AbbVie's growth?

Skyrizi (up 30.9%) and Rinvoq (up 23.3%) in immunology are driving growth.

Have analysts recommended buying AbbVie stock?

No official buy recommendation has been issued, but positive results support bullish views.

AbbVie Stock on Track to Hit $300: Analyst Target in Focus

Following better-than-expected Q1 2026 results, analysts see AbbVie stock hitting $300. Immunology revenue reached $7.29 billion, driven by Skyrizi (+30.9%) and Rinvoq (+23.3%).

June 16, 2026

2 min read

Source: 24/7 Wall St.

Key Numbers

immunology revenue

7.29B

skyrizi growth

30.9%

rinvoq growth

23.3%

Investors are eyeing AbbVie (NYSE:ABBV) after its Q1 2026 results exceeded expectations, prompting some analysts to set a $300 price target. CEO Robert A. Michael called the start "excellent," with immunology revenue at $7.29 billion.

Rating Change

No official rating change has been announced, but the positive outlook is based on strong fundamentals. The stock currently trades below $300, implying potential upside.

Analyst Rationale

Analysts highlight the growth of Skyrizi (+30.9%) and Rinvoq (+23.3%) in the immunology segment, which are key revenue drivers. Management expressed confidence in sustaining momentum.

Context

AbbVie's 2026 performance follows a challenging 2025 due to patent expirations. Other analysts monitor how the company offsets declining Humira sales.

What to Make of It

Despite optimism, investors should watch regulatory and competitive risks. The $300 target hinges on continued immunology growth and meeting guidance.

Frequently Asked Questions

Some analysts expect AbbVie stock to reach $300 based on strong Q1 2026 results.

Found this useful? Share it

This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.